AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB1 day ago · The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson's disease.
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB1 day ago · AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1 ...
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
WEB11 hours ago · The trial evaluated a once-a-day dose of tavapadon to treat Parkinson’s as an adjunctive treatment to levodopa (LD) in 507 patients aged 40-80 years. The trial met its primary endpoint and key ...
News
WEB1 day ago · Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease. The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson's disease.
Abbvie drug improves Parkinson's symptoms in trial - STAT
WEB1 day ago · Annual. $399. Save 15%. Get Started. View All Plans. AbbVie's Parkinson’s drug, tavapadon, which it got from Cerevel Therapeutics, alleviated symptoms in a Phase 3 trial.
Parkinson Agent Tavapadon Meets Primary and Secondary End …
WEB1 day ago · All told, tavapadon showed a safety profile that was consistent with previous observations, with a majority of the AEs being mild to moderate in severity. REFERENCES 1. AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease. …
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its …
WEB1 day ago · Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease. AbbVie added the drug candidate with its $8.7 billion ...
Cerevel Therapeutics Announces Positive Topline Results for …
WEBApr 18, 2024 · Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD.
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's …
WEB1 day ago · AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline ...
AbbVie Announces Positive Topline Results From Phase 3 …
WEB1 day ago · AbbVie announced positive topline results from its pivotal phase three TEMPO-1 trial evaluating tavapadon as a standalone treatment for early-stage Parkinson’s disease (PD), according to a news release. 1 Tavapadon, an investigational D1/D5 dopamine receptor partial agonist, is being investigated as a once-daily treatment for the condition.
- Some results have been removed
Skip to content